TScan Therapeutics Inc. (NASDAQ:TCRX) saw a downside of -0.95% to close Monday at $2.08 after subtracting -$0.02 on the day. The 5-day average trading volume is 1,237,460 shares of the company’s common stock. It has gained $2.67 in the past week and touched a new high 2 times within the past 5 days. An average of 338,700 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 149,294.
TCRX’s 1-month performance is 30.00% or $0.57 on its low of $1.45 reached on 12/27/22. The company’s shares have touched a 52-week low of $1.45 and high of $5.60, with the stock’s rally to the 52-week high happening on 01/23/23. YTD, TCRX has achieved 34.19% or $0.53 and has reached a new high 7 times. However, the current price is down -62.84% from the 52-week high price.
Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.73 while the price-to-book (PB) in the most recent quarter is 0.43.
TScan Therapeutics Inc.’s quick ratio for the period ended June 29 was 8.50, with the current ratio over the same period at 8.50. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.25, while the total debt to equity was 0.25. The firm’s gross profit as reported stood at $58.78 million against revenue of $10.14 million.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 2.52% to -$16.25 million, while revenue of -$15.1 million was 7.08% off the previous quarter. Analysts expected TCRX to announce -$0.75 per share in earnings in its latest quarter, but it posted -$0.63, representing a 16.00% surprise. EBITDA for the quarter stood at more than -$15.33 million. TCRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 48.8 million, with total debt at $5.24 million. Shareholders hold equity totaling $24.08 million.
Let’s look briefly at TScan Therapeutics Inc. (TCRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 55.67% to suggest the stock is trending Neutral, with historical volatility in this time period at 198.18%.
The stock’s 5-day moving average is $2.07, reflecting a -5.45% or -$0.12 change from its current price. TCRX is currently trading +22.35% above its 20-day SMA, -23.81% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -19.07% and SMA200 by-25.45%.
Stochastic %K and %D was 60.12% and 60.62% and the average true range (ATR) pointed at 0.34. The RSI (14) points at 53.57%, while the 14-day stochastic is at 44.86% with the period’s ATR at 0.32. The stock’s 9-day MACD Oscillator is pointing at 0.07 and 0.15 on the 14-day charts.
Analysts offering their rating for TCRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate TCRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 4 have offered a “buy” rating.
What is TCRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $21.00, with their median price target at $14.50. Looking at these predictions, the average price target given by analysts is for TScan Therapeutics Inc. (TCRX) stock is $14.00.